Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen
Acta Haematologica · 2024
DOI: 10.1159/000533944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Leona A Holmberg und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Vorinostat, Bortezomib, Lymphoma, Non-Hodgkin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
The success of autologous stem cell transplantation (ASCT) for treating non-Hodgkin’s lymphoma (NHL) is limited by its high relapse rates. To reduce the risk of relapse, additional maintenance therapy can be added post-transplant. In a non-transplant setting at the time of initiation of this study, both bortezomib and vorinostat had been studied alone or in combination for some NHL histology and showed some clinical activity. At our center, this combination therapy post-transplant for multiple myeloma showed acceptable toxicity. Therefore, it seemed reasonable to study this combination therapy post-ASCT for NHL.
Methods
NHL patients underwent conditioning for ASCT with rituximab, carmustine, etoposide, cytarabine, melphalan/carmustine, etoposide, cytarabine, melphalan. After recovery from the acute transplant-related toxicity, combination therapy with IV bortezomib and oral vorinostat (BV) was started and was given for a total of 12 (28-day) cycles.
Results
Nineteen patients received BV post-ASCT. The most common toxicities were hematologic, gastrointestinal, metabolic, fatigue, and peripheral neuropathy. With a median follow-up of 10.3 years, 11 patients (58%) are alive without disease progression and 12 patients (63%) are alive.
Conclusions
BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Medicine, University of Washington, Seattle, Washington, USA.
Zitieren
APA
Holmberg, L. A., Maloney, D. G., & Connelly-Smith, L. (2024). Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen. Acta Haematologica. https://doi.org/10.1159/000533944
Vancouver
Holmberg LA, Maloney DG, Connelly-Smith L. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen. Acta Haematologica. 2024. doi:10.1159/000533944
BibTeX
@article{Holmberg2024,
author = {Holmberg, Leona A and Maloney, David G and Connelly-Smith, Laura},
title = {Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000533944}
}
EUVIMED